Finance

Lists
Q2 2026 earnings • released • EPS met 0.00% • Revenue beat +1.66%
See results
PHAT:NASDAQ
Phathom Pharmaceuticals Inc
$8.75
-3.10%
(-0.28) 1D
$8.74
-0.11% (-0.010)
After hours
Closed: Jul 31, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for PHAT...
Open
$9.10
High
$9.49
Low
$8.66
Mkt. cap
697.86M
Avg. vol.
1.29M
Volume
3.31M
52-wk high
$18.31
52-wk low
$8.02
EPS
-$2.11
Beta
0.49
Shares outstanding
79.76M
No. of employees
371
Open
$9.10
High
$9.49
Low
$8.66
Mkt. cap
697.86M
Avg. vol.
1.29M
Volume
3.31M
52-wk high
$18.31
52-wk low
$8.02
EPS
-$2.11
Beta
0.49
Shares outstanding
79.76M
No. of employees
371
News stories
From sources across the web
About Phathom Pharmaceuticals Inc
CEO-
Employees371
Founded2018
HeadquartersFlorham Park, New Jersey, United States
SectorPharmaceutical industry
Websitephathompharma.com
Analyst ratings
Based on 6 analysts giving stock ratings to PHAT in the past 3 months
Strong buy
Buy
6
Hold
0
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for PHAT in the last 3 months.
Highest
Current $8.75
$26.00 (+197.14%)
Average
$21.50 (+145.71%)
Lowest
$18.00 (+105.71%)
Analyst
Recommendation
Action
Price target
Projected
Date
Chase Knickerbocker
Craig-Hallum
Buy
Reiterated
$20.00
+128.6%
07/31/2026
Martin Auster
Raymond James
Buy
Maintained
$21.00
+140%
07/31/2026
Yatin Suneja
Guggenheim
Buy
Maintained
$22.00
+151.4%
07/31/2026
Matthew Caufield
H.C. Wainwright
Buy
Reiterated
$26.00
+197.1%
07/31/2026
Joseph Stringer
Needham
Buy
Maintained
$22.00
+151.4%
07/30/2026
Jenna Davidner
Barclays
Buy
Maintained
$18.00
+105.7%
05/15/2026
Paul Choi
Goldman Sachs
Hold
Maintained
-
-
04/30/2026
Last report
Jul 30, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
/ -$0.10
0.00%miss
Revenue / Est. (USD)
74.27M / 73.06M
+1.66%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
49.50M
57.58M
58.30M
74.27M
Cost of goods sold
6.19M
7.65M
12.00M
15.10M
Cost of revenue
6.19M
7.65M
12.00M
15.10M
Research and development expenses
7.03M
7.49M
7.77M
7.81M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
51.56M
48.37M
54.01M
55.33M
Operating expense
58.58M
55.86M
61.78M
63.14M
Total operating expenses
64.78M
63.51M
73.78M
78.24M
Operating income
-15.27M
-5.93M
-15.48M
-3.96M
Other non operating income
-7.00K
-5.00K
-831.00K
-24.00K
EBT including unusual items
-29.97M
-21.15M
-30.37M
-17.58M
EBT excluding unusual items
-29.97M
-21.15M
-30.37M
-17.58M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-29.97M
-21.15M
-30.37M
-17.58M
Net profit margin
-60.55%
-36.73%
-52.09%
-23.67%
Earnings per share
-0.15
-0.08
-0.18
-
Interest and investment income
1.41M
1.20M
1.74M
1.51M
Interest expense
-16.11M
-16.42M
-15.80M
-15.10M
Net interest expenses
-14.70M
-15.22M
-14.06M
-13.59M
Depreciation and amortization charges
-
-
-
-
EBITDA
-15.12M
-5.80M
-15.37M
-3.85M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps